Francesco Lupo Conte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Francesco Lupo Conte has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Donata Villari
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
1 shared publication - Enrico Mini
Department of Health Sciences, University of Florence, 50139 Florence, Italy
1 shared publication - Francesco Sessa
Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50134 Florence, Italy
1 shared publication - Gabriella Nesi
University of Florence
1 shared publication - Giandomenico Roviello
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence
1 shared publication - Ilaria Camilla Galli
Histopathology and Molecular Diagnostics, Careggi University Hospital, 50134 Florence, Italy
1 shared publication
Latest Publications
- Open Access
- 3 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 866
Inflammation in Urological Malignancies: The Silent Killer
Several studies have investigated the role of inflammation in promoting tumorigenesis and cancer progression. Neoplastic as well as surrounding stromal and inflammatory cells engage in well-orchestrated reciprocal interactions to establish an inflammatory tumor microenvironment. The tumor-associated inflammatory tissue is highly plastic, capable of continuously modifying its phenotypic and functional characteristics. Accumulating evidence suggests that chronic inflammation plays a critical role in the development of urological cancers. Here, we review the origins of inflammation in urothelial, prostatic, renal, testicular, and penile cancers, focusing on the mechanisms that drive tumor initiation, growth, progression, and metastasis. We also discuss how tumor-associated inflammatory tissue may be a diagnostic marker of clinically significant tumor progression risk and the target for future anti-cancer therapies.
- 3 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 866
Open AccessInflammation in Urological Malignancies: The Silent Killer
Several studies have investigated the role of inflammation in promoting tumorigenesis and cancer progression. Neoplastic as well as surrounding stromal and inflammatory cells engage in well-orchestrated reciprocal interactions to establish an inflammatory tumor microenvironment. The tumor-associated inflammatory tissue is highly plastic, capable of continuously modifying its phenotypic and functional characteristics. Accumulating evidence suggests that chronic inflammation plays a critical role in the development of urological cancers. Here, we review the origins of inflammation in urothelial, prostatic, renal, testicular, and penile cancers, focusing on the mechanisms that drive tumor initiation, growth, progression, and metastasis. We also discuss how tumor-associated inflammatory tissue may be a diagnostic marker of clinically significant tumor progression risk and the target for future anti-cancer therapies.